通过寻找网络控制中心来识别作为治疗靶点的癌症保持基因
Identification of cancer-keeping genes as therapeutic targets by finding network control hubs
摘要:
寻找癌症驱动基因一直是癌症研究和临床研究的焦点。最近的一种方法是基于网络结构可控性,其重点是找到一种控制方案和驱动基因,可以将细胞从任意状态引导到指定状态。虽然理论上是合理的,但由于许多原因,这种方法是不切实际的,例如,控制方案通常不是唯一的,并且一半的节点可以是细胞的驱动基因。我们开发了一种超越结构可控性的新方法。我们没有考虑一个控制方案的驱动基因,而是考虑了位于每个控制方案的控制路径中间的控制中心基因。控制中枢是控制细胞最脆弱的部位,外源性刺激可能使细胞无法控制。我们采用控制枢纽作为癌保持基因(CKG),并将其应用于膀胱癌(BLCA)的基因调控网络。BLCA中细胞周期和p53信号通路上的所有基因都是CKG,证实了这些基因和这两条通路在癌症中的重要性。通过删除网络链接,确定了BLCA的35个敏感CKG(sCKG)的较小集合。在四种细胞系中对六种sCKG(RPS 6 KA 3、FGFR 3、N-钙粘蛋白(CDH 2)、EP 300、半胱天冬酶-1和FN 1)进行小干扰RNA敲低,以验证它们对癌细胞增殖或迁移的影响。在BLCA小鼠模型中敲低RPS 6 KA 3显著抑制了小鼠模型中肿瘤异种移植物的生长。结合,我们的研究结果表明CKG作为癌症治疗的治疗靶点的价值和CKG作为研究和表征癌症病因学的有效手段的潜力。
英文摘要:
Finding cancer driver genes has been a focal theme of cancer research and clinical studies. One of the recent approaches is based on network structural controllability that focuses on finding a control scheme and driver genes that can steer the cell from an arbitrary state to a designated state. While theoretically sound, this approach is impractical for many reasons, e.g., the control scheme is often not unique and half of the nodes may be driver genes for the cell. We developed a novel approach that transcends structural controllability. Instead of considering driver genes for one control scheme, we considered control hub genes that reside in the middle of a control path of every control scheme. Control hubs are the most vulnerable spots for controlling the cell and exogenous stimuli on them may render the cell uncontrollable. We adopted control hubs as cancer-keep genes (CKGs) and applied them to a gene regulatory network of bladder cancer (BLCA). All the genes on the cell cycle and p53 singling pathways in BLCA are CKGs, confirming the importance of these genes and the two pathways in cancer. A smaller set of 35 sensitive CKGs (sCKGs) for BLCA was identified by removing network links. Six sCKGs (RPS6KA3, FGFR3, N-cadherin (CDH2), EP300, caspase-1, and FN1) were subjected to small-interferencing-RNA knockdown in four cell lines to validate their effects on the proliferation or migration of cancer cells. Knocking down RPS6KA3 in a mouse model of BLCA significantly inhibited the growth of tumor xenografts in the mouse model. Combined, our results demonstrated the value of CKGs as therapeutic targets for cancer therapy and the potential of CKGs as an effective means for studying and characterizing cancer etiology.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。